Cross-disease approaches to treating the onset, exacerbation and progression of chronic lung diseases
DAY 3
Chaired by: Professor David Lomas (London) and Dr Samantha Walker (ALUK)
| 1:45 pm |
New and known pathological pathways as novel targets during the early phases of chronic respiratory disease |
| 2:15 pm |
Preventing acute microbial-driven exacerbations from destabilising lung function and worsening chronic disease |
| 2:45 pm |
Opportunities for targeting common cross-disease mechanisms to prevent progression of chronic lung diseases |
1:45 PM
90 MINUTE SESSION
Learning objectives
- Explore common pathways and targets, with treatment potential across different stages of chronic respiratory disease, where focused research would accelerate drug discovery.
- Understand how increased efforts in developing specific research tools are needed to make significant progress towards the development of new treatments, including increased effort towards biomarker development across respiratory diseases.
- Provide insight into how taking a cross-disease and cross-discipline approach can facilitate collaborations that drive the development of tools (biomarkers) and treatments (drugs) that are truly disease-modifying, and what key elements can drive impactful collaborations.
Speakers
i
BIOGRAPHY
Dr Renata Jurkowska, Reader and UKRI Future Leaders Fellow, School of Biosciences, Cardiff University, is a molecular biologist with general interests in epigenetics, stem cells, and lung biology. She obtained her M.Sc. degree in Biotechnology at Warsaw University (Poland), completed her PhD, and two postdocs in Germany before joining BioMed X Innovation Center (Germany), where she worked at the interface between academia and industry, leading a biomedical preclinical project in the field of respiratory medicine.
She is currently a Reader at the School of Biosciences at Cardiff University (UK) and, since 2024, also a UKRI Future Leaders Fellow. Her research focuses on understanding epigenetic mechanisms driving the development of lung diseases. Her group employs sequencing-based approaches in combination with cutting-edge epigenetic editing tools and organoid models to advance the biological understanding of lung cell regeneration and accelerate the discovery of epigenetic therapeutics and biomarkers for respiratory diseases.
Her research has been funded by the Academy of Medical Sciences Springboard Award, BBSRC, UKRI Future Leaders Fellowship, and Wellcome Discovery Award.
Dr Renata Jurkowska